tovecimig
Advanced Solid Tumors
Phase 1Active
Key Facts
About Compass Therapeutics
Compass Therapeutics is a public, clinical-stage biotech focused on developing sophisticated antibody-based immunotherapies for cancer. The company's strategy centers on leveraging its proprietary technology platforms to rapidly generate diverse therapeutic candidates designed to modulate the tumor microenvironment and coordinate a comprehensive immune attack. With a market cap of approximately $930M, Compass is advancing a pipeline of novel agents, with its lead candidate, tovecimig, in clinical development, aiming to address significant unmet needs in oncology.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |